Project Details
Description
A double-blind, randomized, placebo-controlled, parallel group, Phase IIa trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics and efficacy of BI 765423 administered intravenously on top of standard of care in patients with IPF
| Status | Not started |
|---|---|
| Effective start/end date | 12/1/25 → 12/31/27 |
Funding
- BOEHRINGER-INGELHEIM PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.